Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Business Wire•02/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $110.0 million, down 52% year over year
- ➤Q3 net loss $32.7 million versus $51.2 million net income
- ➤Q3 adjusted EBITDA loss $4.6 million versus $92.6 million profit
- ➤Completed repurchase of $75 million aggregate principal Senior Unsecured Notes
- ➤CYFENDUS contract modification awarded, valued at approximately $24 million
Expert Statements
Joe Papa, President and Chief Executive Officer of Emergent BioSolutions
“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation”
Joe Papa, President and Chief Executive Officer of Emergent BioSolutions
“We remain focused on our turnaround priorities and strengthening our financial position, which includes improving operating performance, reducing debt, creating long-term shareholder value, continuously demonstrating high standards of quality and compliance in all we do and delivering on our mission to protect and save lives.”
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)%
Get started
Create a free account to read the full story.